New partnership to raise awareness of impact of heart disease in people with diabetes
The International Diabetes Federation (IDF) announced the launch of a new global effort to quantify the regional and global burden of cardiovascular disease (CVD) in people with diabetes.
CVD is one of the most common complications associated with diabetes and is responsible for over one third of all deaths in people with diabetes. This project is supported by a grant from the AstraZeneca/Bristol Myers Squibb Diabetes Alliance.
Through this multi-pronged effort, IDF will work toward the publication of an update to the 2001 publication Time to Act: Diabetes & Cardiovascular Disease in collaboration with a global panel of experts assembled by IDF. The updated publication will:
Raise public awareness about the links between diabetes and CVD
Update the evidence base for CVD and diabetes
Enable global and national policy makers to make informed decisions on diabetes
- Influence policy and discussion around diabetes in the post-2015 development agenda
The project will be carried out in three phases over the course of two years:
A scientific literature review on CVD in people with diabetes
Establishment of a model for estimating the burden of CVD in people with diabetes
- Generation of global and regional estimates of the burden of CVD in people with diabetes
IDF will ensure that the project produces the data needed to mobilize and strengthen the global diabetes community and to drive the fight against diabetes on all levels of society worldwide.
For further questions and interviews contact:
Sara Webber PR Coordinator
+32 496 12 94 70
Parliamentarians Take Up Global Diabetes Challenge with the “Melbourne Declaration”
Members of more than 50 Parliaments have committed themselves to tackling the global challenge posed by the surging worldwide diabetes pandemic.
The Parliamentarians released the Melbourne Declaration on Diabetes at the World Diabetes Congress of the International Diabetes Federation (IDF) in Melbourne, Australia today.
The Declaration was agreed at the first-ever Parliamentary Champions For Diabetes Forum held in Melbourne earlier this week. The Declaration has established the Parliamentarians for Diabetes Global Network. The Parliamentarians decided to act in light of new International Diabetes Federation (IDF) data estimating that by 2035 there will be 600 million people with diabetes, about one in ten of the world’s population, and a further 450 million at risk of developing the disease.
The Declaration acknowledges the increasingly serious social, economic and medical threat faced by nations large and small by the increasing diabetes pandemic.
The signatories have committed themselves to working across Parliaments to ensure that diabetes is high on the political agenda in every country. They want to see more preventative work, and then early diagnosis, management and access to adequate care, treatment and medicines is available for all those living with diabetes.
Welcoming the Declaration, the President of the International Diabetes Federation Sir Michael Hirst said “This is an important moment in the political battle to ensure that governments understand the threat the world faces from diabetes. This is a global challenge requiring a global response. The Melbourne Declaration provides our parliamentary supporters with the tools to raise the issue in every country across the world and press for change”.
The Hon. Judi Moylan is the Global Coordinator of the Parliamentarians for Diabetes Global Network with British MP Adrian Sanders as President. Simon Busuttil, Malta’s opposition leader and Dr Rachel Nyamai MP from Kenya are Vice-Presidents. Sir Michael Hirst, President of the International Diabetes Federation (IDF) and Guy Barnett, a former Australian Senator and Co-Chairs of the Forum are ex-officio members of the Executive Committee.
Download here The Melbourne Declaration on Diabetes.
For further information, contact David Hallam +32 (0)471 257 333 or Guy Barnett +61 (0) 428 622333.
Notes for editors:
Diabetes is a major threat to the health and productivity of all nations. Diabetes is a leading cause of blindness, amputations, kidney failure, heart attacks and stroke, and early death. Disadvantaged people in every country carry the greatest burden and indigenous communities are especially vulnerable.
However, there are solutions for managing and preventing the diabetes pandemic and we need to embrace them now.
The International Diabetes Federation (IDF) is the global advocate for the more than 382 million people with diabetes worldwide as well as their families and healthcare providers. IDF is a non-governmental organisation of over 200 member associations in more than 160 countries in official relations with the World Health Organization and is associated with the Department of Public Information of the United Nations. The mission of the International Diabetes Federation is to promote diabetes care, prevention and a cure worldwide.
Early Type 2 Diabetes conversations survey launched today
The International Diabetes Federation is very pleased to announce the launch of the largest multinational survey to investigate early conversations between physicians and people living with Type 2 Diabetes (T2D).
This survey, led by Boehringer Ingelheim and Eli Lilly and Company, was developed in partnership with the International Diabetes Federation (IDF) and will include more than 10,000 people with T2D and more than 6,500 treating-physicians across 26 countries worldwide.
It will help to optimise the early conversations between patients and physicians and advance the quality of diabetes care worldwide.
You can download the press release here.
IDF Europe study on Access to Quality Medecines & Medical Devices for Diabetes Care in Europe now online!
Following the launch of the initial findings of the study on 13 November, the full IDF Europe study on Access to Quality Medicines and Medical Devices for Diabetes Care in Europe is now available online.
The first of its kind in the field of diabetes, the study highlights disparities in access to medicines and devices for diabetes care in the 47 countries of the IDF Europe Region. The report aims to provide evidence to policy makers and stakeholders on the current challenges faced by people living with diabetes in terms of access to the treatment they need.
Based on over 1,150 answers to a survey questionnaire, interviews and desk research, the study assesses key dimensions of access (availability, accessibility, affordability, quality and equity) for a range of treatment options used in diabetes care at national level, while offering a comparative, regional perspective that may inspire new solutions based on other countries’ experiences.
Country fact-sheets and sub-regional analysis are available here.